Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SLN vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)

SLN Overall Winner 6-Pillar Tally: SLN 2 – 2 CAMP (2 Tie) Matrix Metrics: SLN 6 – 1 CAMP

As of Nov 17, 2026, Silence Therapeutics Plc American Depository Share (SLN) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SLN carries a Unified Composite Score of 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -10475.6% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLN vs CAMP
SLN NASDAQ Head-to-Head Winner
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.80
+0.03% 1D
Market Cap $1.2B
TTM Revenue $615,000
Forward P/E N/M
Beta / 30D Vol 1.92β · 4% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 25.0 Fund 34.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.7% over 20 days), RSI 77
RSI-14: 76.9 · SMA20: $19.76 · SMA50: $14.89
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.35β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (SLN 2 – 2 CAMP)

Columns: Metric · SLN · CAMP
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 26.6x
2. Growth & Scale SLN
Revenue Growth (YoY) +197.2% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $615,000 $5.3M
Market Cap $1.2B $238.5M
3. Profitability & Quality SLN
Gross Margin 85.9% N/A
Operating Margin -10475.6% -991.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -90.4% -146.1%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$64M EBITDA -$26M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.32 Book/Sh · -90.4% ROE $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 55.4% (50th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLN (6) vs CAMP (1)
Institutional Metric SLN CAMP Criterion Row Edge
Market Capitalization
Scale
$1.2B $238.5M Larger Scale SLN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+197.2% +138.9% Higher Growth SLN
Operating Margin (TTM)
Profitability
-10475.6% -991.8% Higher Margin CAMP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-90.4% -146.1% Higher ROE SLN
52-Week Range Position
Momentum
100% ($4–$20) 23% ($3–$8) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.92β · 4% Vol 1.35β · 94% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite SLN
Trailing 12M Revenue (USD)
Operating Scale
$615,000 $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M EBITDA ($1.32 Book/Sh · -90.4% ROE) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +26.24 pp
SLN: +1.15% · CAMP: +27.39%
3M Horizon SLN +59.5 pp
SLN: +45.52% · CAMP: -13.98%
6M Horizon SLN +246.85 pp
SLN: +243.24% · CAMP: -3.61%
1Y Horizon SLN +192.41 pp
SLN: +189.97% · CAMP: -2.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs CAMP. Trailing 12-month operating profitability (SLN -10475.6% vs CAMP -991.8%) and valuation multiples (SLN N/M vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$615,000
Gross Margin85.9%
Op. Margin-10475.6%
ROE / Fwd P/E-90.4% · N/M
CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -10475.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLN vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, Silence Therapeutics Plc American Depository Share (SLN) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SLN carries a Unified Composite Score of 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -10475.6% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin). Technically, SLN sits in a Markup phase (RSI 76.9, UNCLASSIFIED options structure) and CAMP sits in a Neutral phase (RSI 51.9, UNCLASSIFIED options structure).

SLN leads the Growth & Scale pillar: SLN posts +197.2% YoY revenue growth and +0.0% YoY earnings growth on $615,000 TTM revenue (85.9% gross margin, -10475.6% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). On trailing 12-month operating scale, SLN generates $615,000 in USD-normalized revenue versus $5.3M for CAMP. In operating R&D and SG&A reinvestment, SLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

CAMP screens cheaper on headline valuation multiples. SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLN (-90.4% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 4% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.